EFFICACY AND TOLERABILITY OF GENERIC ZOLEDRONIC ACID 5 MG (REZOCLASTIN PS) IN THE TREATMENT OF OSTEOPOROSIS: A RETROSPECTIVE ANALYSIS OF CLINICAL EXPERIENCE WITH THE DRUG IN RUSSIA
| Autor: | L A Marchenkova, A V Dreval, I V Baharev |
|---|---|
| Jazyk: | English<br />Russian |
| Rok vydání: | 2014 |
| Předmět: | |
| Zdroj: | Остеопороз и остеопатии, Vol 17, Iss 3, Pp 22-26 (2014) |
| Druh dokumentu: | article |
| ISSN: | 2072-2680 2311-0716 |
| DOI: | 10.14341/osteo2014322-26 |
| Popis: | Objectives. To analyze clinical data of the first domestic zoledronic acid generic preparation for the treatment of osteoporosis (Rezoclastin PS., 5 mg). Materials and Methods. The study included data from 123 patients (118 women and 5 men) treated with Rezoclastin PS 5 mg in medical centers of Moscow, St.-Petersburg and Krasnodar for primary (91.8%) or secondary(8.2%) osteoporosis, with mean age 27-78 years (61,4 ± 9,1 years). 56.6% of patients had severe osteoporosis with compressive deformations of vertebrae. Duration of medical therapy ranged from 6 to 24 months. Results. Study of changers in bone resorption marker CTx (n = 10) showed decline by 78% after 3 months of treatment compared to baseline (p = 0.027). BMD at the lumbar segment of the spine L 1-L 4 increased after 12 months by 3.4% (p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|